[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemocompatibility-related-adverse-event\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemocompatibility-related-adverse-event":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":38,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100642101",false,"NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.","ALL","18 Years",{"count":19,"type":20},370,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[26,27,28,29,30,31,32,33,34,35,36,37],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Bleeding","Thrombosis","Stroke","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antiplatelet Therapy","Antithrombotic Therapy",[39,27,32,30,31,40,35,41],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":45,"type":46},"2026-06-12","ACTUAL",{"date":48,"type":20},"2026-06-25",{"date":50,"type":20},"2029-12-31",{"name":52,"class":53},"China National Center for Cardiovascular Diseases","OTHER_GOV",""]